Loading company…
Yixuan Biology develops nucleic acid-based therapeutics using precision delivery technology.
Yixuan Biology develops nucleic acid therapies for chronic and aging-related diseases and conducts medical research and experimental development. Founded in 2025 and based in Shanghai, China, it raised angel funding in August 2025, co-led by FIRHealth Capital and Frees Fund, with Yongkan Investment participating.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in